The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The protections extend through at least 2035, with the potential for further extensions
Subscribe To Our Newsletter & Stay Updated
